U.S. markets closed
  • S&P 500

    4,080.07
    +122.44 (+3.09%)
     
  • Dow 30

    34,589.77
    +737.24 (+2.18%)
     
  • Nasdaq

    11,468.00
    +484.22 (+4.41%)
     
  • Russell 2000

    1,874.79
    +38.24 (+2.08%)
     
  • Crude Oil

    80.59
    +2.39 (+3.06%)
     
  • Gold

    1,783.50
    +19.80 (+1.12%)
     
  • Silver

    22.36
    +0.93 (+4.33%)
     
  • EUR/USD

    1.0408
    +0.0073 (+0.71%)
     
  • 10-Yr Bond

    3.7030
    -0.0450 (-1.20%)
     
  • GBP/USD

    1.2053
    +0.0103 (+0.87%)
     
  • USD/JPY

    138.0490
    -0.5850 (-0.42%)
     
  • BTC-USD

    17,080.89
    +588.35 (+3.57%)
     
  • CMC Crypto 200

    405.99
    +5.29 (+1.32%)
     
  • FTSE 100

    7,573.05
    +61.05 (+0.81%)
     
  • Nikkei 225

    27,968.99
    -58.85 (-0.21%)
     

Is This Growth Stock Undervalued?

Is This Growth Stock Undervalued?

Biotech company Bluebird Bio (NASDAQ: BLUE) is currently riding high. Despite these accomplishments, Bluebird is still a tiny company with a market cap of just $475 million. Of note, Skysona had previously earned marketing authorization in Europe, but Bluebird exited the European market last year for reasons that may also prove to be a challenge in the U.S. (more on that in a bit).